Listed by the USPTO as SAMALA, JAGADISHWAR RAO
Tech Center 1600 • Art Units: 1618
This examiner grants 68% of resolved cases
SAMALA, JAGADISHWAR RAO works in Tech Center 1600 and Art Unit 1618. The data records 798 resolved cases and a 67.9% allowance rate. The 1177-day median to allowance suggests that applicants should expect a prosecution process requiring sustained attention, with enough time reserved for substantive responses and possible claim refinement.
The interview lift is 55.7%, the strongest stated positive association in this profile. That result supports treating a focused interview as a potentially important part of prosecution planning when the applicant can explain technical distinctions clearly. The leading organizations are Novartis AG, The Johns Hopkins University, and Actinium Pharmaceuticals Inc. Listed firms include Knobbe, Martens, Olson & Bear, LLP, ARENTFOX SCHIFF LLP and CARDINAL HEALTH, and Dentons Cohen & Grigsby P.C.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18628570 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | Final Rejection | NOVARTIS AG |
| 18440783 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | Non-Final OA | NOVARTIS AG |
| 18772628 | PSMA-BINDING AGENTS AND USES THEREOF | Non-Final OA | The Johns Hopkins University |
| 18754996 | SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | Non-Final OA | The Johns Hopkins University |
| 18577453 | COMPOSITIONS AND METHODS RELATING TO CELLS WITH ADHERED PARTICLES | Non-Final OA | PRESIDENT AND FELLOWS OF HARVARD COLLEGE |
| 18779607 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | Non-Final OA | Cornell University |
| 18730243 | PH-SENSITIVE FLUOROPHORES | Non-Final OA | Georgia State University Research Foundation, Inc. |
| 18684103 | RADIOIMMUNOCONJUGATES TARGETING CALRETICULIN FOR USE IN THE TREATMENT OF CANCER | Non-Final OA | ACTINIUM PHARMACEUTICALS, INC. |
| 16627872 | TREATMENTS FOR A HEMATOLOGICAL MALIGNANCY | Final Rejection | Actinium Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy67.9% of resolved applications examined by Jagadishwar Rao Samala were allowed (798 resolved cases), compared with 33.1% across Art Unit 1618 over the last five years.
This examiner's interview lift is +55.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jagadishwar Rao Samala took 1,177 days on average from filing to allowance.
Jagadishwar Rao Samala examines applications in Art Unit 1618 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
